Larimar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	177.91	85.41	33.22	26.75	26.83	70.1
Short-Term Investments	22.47	51.44	150.24	60.04	91.6	-
Cash & Short-Term Investments	200.39	136.85	183.45	86.79	118.43	70.1
Cash Growth	27.21%	-25.40%	111.38%	-26.71%	68.95%	-24.33%
Other Current Assets	4.59	5.17	11.85	3.39	2.31	2.11
Total Current Assets	204.98	142.02	195.3	90.18	120.74	72.2
Net Property, Plant & Equipment	2.42	2.69	3.72	3.76	3.69	4.46
Other Long-Term Assets	1.11	1.13	1.2	2	1.98	2.01
Total Assets	208.51	145.84	200.23	95.94	126.41	78.67
Accounts Payable	8.58	5.22	2.42	1.28	1.69	1.66
Accrued Expenses	38.12	58.47	20.87	7.39	8.41	6.59
Current Portion of Leases	1.06	1.11	1.06	0.84	0.61	0.59
Total Current Liabilities	47.76	64.8	24.36	9.51	10.71	8.85
Long-Term Leases	2.72	2.96	4.06	4.71	4.8	5.41
Total Long-Term Liabilities	2.72	2.96	4.06	4.71	4.8	5.41
Total Liabilities	50.48	67.76	28.41	14.22	15.5	14.25
Common Stock	0.1	0.08	0.06	0.04	0.04	0.02
Additional Paid-in Capital	622.37	512.78	440.76	270.15	262.5	180.65
Accumulated Other Comprehensive Income	0.01	0.05	0.15	0.08	-0.03	-
Retained Earnings	-464.44	-434.83	-269.16	-188.55	-151.61	-116.25
Shareholders' Equity	158.03	78.09	171.81	81.72	110.9	64.41
Total Liabilities & Equity	208.51	145.84	200.23	95.94	126.41	78.67
Total Debt	3.78	4.07	5.12	5.55	5.41	6
Net Cash (Debt)	196.61	132.79	178.34	81.24	113.02	64.1
Net Cash Growth	48.06%	-25.54%	119.51%	-28.12%	76.33%	-25.58%
Net Cash Per Share	2.48	1.82	2.91	1.85	4.39	3.73
Book Value	158.03	78.09	171.81	81.72	110.9	64.41
Book Value Per Share	1.99	1.07	2.80	1.86	4.31	3.75
Tangible Book Value	158.03	78.09	171.81	81.72	110.9	64.41
Tangible Book Value Per Share	1.99	1.07	2.80	1.86	4.31	3.75

SEC Filings: 10-K · 10-Q